Literature DB >> 1716683

2-Pyridinone derivatives: a new class of nonnucleoside, HIV-1-specific reverse transcriptase inhibitors.

W S Saari1, J M Hoffman, J S Wai, T E Fisher, C S Rooney, A M Smith, C M Thomas, M E Goldman, J A O'Brien, J H Nunberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1716683     DOI： 10.1021/jm00113a036

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


× No keyword cloud information.
  9 in total

1.  Quantitative structure-activity relationship analysis of pyridinone HIV-1 reverse transcriptase inhibitors using the k nearest neighbor method and QSAR-based database mining.

Authors:  Jose Luis Medina-Franco; Alexander Golbraikh; Scott Oloff; Rafael Castillo; Alexander Tropsha
Journal:  J Comput Aided Mol Des       Date:  2005-04       Impact factor: 3.686

2.  The PETT series, a new class of potent nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase.

Authors:  C Ahgren; K Backro; F W Bell; A S Cantrell; M Clemens; J M Colacino; J B Deeter; J A Engelhardt; M Hogberg; S R Jaskunas
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

3.  Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro- 5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)]-beta-D-pentofurano syl (TSAO) nucleoside analogues retain sensitivity to HIV-1-specific nonnucleoside inhibitors.

Authors:  J Balzarini; A Karlsson; A M Vandamme; M J Pérez-Pérez; H Zhang; L Vrang; B Oberg; K Bäckbro; T Unge; A San-Félix
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-01       Impact factor: 11.205

4.  A nonnucleoside reverse transcriptase inhibitor active on human immunodeficiency virus type 1 isolates resistant to related inhibitors.

Authors:  M E Goldman; J A O'Brien; T L Ruffing; W A Schleif; V V Sardana; V W Byrnes; J H Condra; J M Hoffman; E A Emini
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

5.  L-696,229 specifically inhibits human immunodeficiency virus type 1 reverse transcriptase and possesses antiviral activity in vitro.

Authors:  M E Goldman; J A O'Brien; T L Ruffing; J H Nunberg; W A Schleif; J C Quintero; P K Siegl; J M Hoffman; A M Smith; E A Emini
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

6.  Identification of the human immunodeficiency virus reverse transcriptase residues that contribute to the activity of diverse nonnucleoside inhibitors.

Authors:  J H Condra; E A Emini; L Gotlib; D J Graham; A J Schlabach; J A Wolfgang; R J Colonno; V V Sardana
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

7.  Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors.

Authors:  V W Byrnes; V V Sardana; W A Schleif; J H Condra; J A Waterbury; J A Wolfgang; W J Long; C L Schneider; A J Schlabach; B S Wolanski
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

8.  Effect of template secondary structure on the inhibition of HIV-1 reverse transcriptase by a pyridinone non-nucleoside inhibitor.

Authors:  D B Olsen; S S Carroll; J C Culberson; J A Shafer; L C Kuo
Journal:  Nucleic Acids Res       Date:  1994-04-25       Impact factor: 16.971

9.  Column-switching high-performance liquid chromatographic determination of a 2-pyridinone-based human immunodeficiency virus type 1 (HIV-1)-specific reverse transcriptase inhibitor in human plasma.

Authors:  E J Woolf; B K Matuszewski
Journal:  Pharm Res       Date:  1993-01       Impact factor: 4.200
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.